These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17216836)
21. Tipranavir (Aptivus) for HIV. Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341 [TBL] [Abstract][Full Text] [Related]
22. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H; Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833 [TBL] [Abstract][Full Text] [Related]
23. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479 [TBL] [Abstract][Full Text] [Related]
24. Tipranavir: a protease inhibitor for HIV salvage therapy. Dong BJ; Cocohoba JM Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094 [TBL] [Abstract][Full Text] [Related]
25. Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients. Feinberg J AIDS Clin Care; 2005 Jan; 17(1):5-6. PubMed ID: 15717371 [No Abstract] [Full Text] [Related]
26. Drug interactions of tipranavir, a new HIV protease inhibitor. Morello J; Rodriguez-Novoa S; Jimenez-Nacher I; Soriano V Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024 [TBL] [Abstract][Full Text] [Related]
32. When and how to use tipranavir and darunavir. Hoffman CJ; Gallant JE AIDS Read; 2007 Apr; 17(4):194-8, 201. PubMed ID: 17479503 [No Abstract] [Full Text] [Related]
34. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Temesgen Z; Feinberg J Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762 [TBL] [Abstract][Full Text] [Related]
35. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report. Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203 [No Abstract] [Full Text] [Related]
36. [Tipranavir optimizes the effect of recent antiretroviral substances. Encouraging options in multiple resistance]. MMW Fortschr Med; 2008 Apr; 150 Spec No 1():71. PubMed ID: 19024922 [No Abstract] [Full Text] [Related]
37. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing. Huff B GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962 [No Abstract] [Full Text] [Related]